ApprovalTrail

Approval · Notice of Compliance 32822 · 2024

SPINRAZA: Notice of Compliance 32822

Issued March 5, 2024

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
32822
Date
March 5, 2024
Company
Biogen Canada IncToronto, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Safety Update to the Product Monograph (PM).

Products in this notice

BrandDINStatus today
SPINRAZANot yet assigned—

Medicinal ingredients